Last reviewed · How we verify
DR-102
DR-102 is a small molecule that inhibits the activity of a specific enzyme.
DR-102 is a small molecule that inhibits the activity of a specific enzyme. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | DR-102 |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Janus kinase inhibitor |
| Target | JAK1 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting this enzyme, DR-102 reduces the production of a key inflammatory mediator, thereby exerting its therapeutic effects.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives (PHASE1)
- A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women (PHASE2)
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |